The Future of Corneal Cross-linking

Myung, David; Manche, Edward E.; Tabibian, David; Hafezi, Farhad

doi:10.1007/978-3-319-39775-7_9

Cited by 2 publications

(1 citation statement)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CXL has in recent years showed promising results when used to treat severe forms of infectious keratitis17, 18, 19, 20, 21, 22, 23, 24, where in such cases the treatment is termed PACK-CXL. The microbicidal effect of PACK-CXL is thought to be mediated through the combined effects of UVA-induced DNA damage and release of reactive oxygen species (ROS) by riboflavin 25 , 26 , while the following post-procedure relief in pain is thought to be mediated by the combined effects of suppression of inflammation 27 and a transient reduction of nociceptive subepithelial nerves 28 …”

Section: Discussionmentioning

confidence: 99%

High fluence PACK-CXL as adjuvant treatment for advanced Acanthamoeba keratitis

Pettersson

Lagali

Mortensen

et al. 2019

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Purpose To describe the outcome of adjuvant high fluence photoactivated chromophore for infectious keratitis cross-linking (PACK-CXL) used to treat an advanced form of refractory Acanthamoeba keratitis (AK) diagnosed several months after initial presentation. Observations An otherwise healthy 24-year old female presented with a severe unilateral keratitis. The diagnosis eluded clinicians for several months and when finally confirmed as AK, anti-amoebic therapy was instated and only appeared to be effective after addition of high fluence PACK-CXL. Conclusion and importance In this case of advanced AK, high fluence PACK-CXL treatment given adjuvant to pharmacologic anti-amoebic therapy resulted in lasting pain relief, re-epithelization and eradication of the Acanthamoeba parasite. Given adjuvant to anti-amoebic pharmacotherapy, high fluence PACK-CXL might be a useful method for treating typically refractory advanced AK.

show abstract

Section: Discussionmentioning

confidence: 99%

High fluence PACK-CXL as adjuvant treatment for advanced Acanthamoeba keratitis

Pettersson

Lagali

Mortensen

et al. 2019

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

show abstract

Corneal collagen cross-linking in mixed etiology keratitis treatment: a case of successful use

Khripun¹,

Владимирович²,

Kobinets

et al. 2021

Ophthalmology Reports

View full text Add to dashboard Cite

Acanthamoeba keratitis with bacterial, fungal superinfection or without it leads to development of an aggressive and long-standing corneal inflammation; up to now, the efficacy of its treatment stays doubtful and demands further investigation. For a long time, there were discussions on the possibility and expediency of corneal collagen cross-linking (PACK-CXL photo activated chromophore for keratitis) in patients with bacterial, fungal and Acanthamoeba keratitis. This article presents a clinical case of effective treatment of mixed etiology keratitis by multiple high fluence accelerated PACK-CXL in a patient with severe local toxico-allergic reaction.

show abstract

The Future of Corneal Cross-linking

Cited by 2 publications

References 89 publications

High fluence PACK-CXL as adjuvant treatment for advanced Acanthamoeba keratitis

High fluence PACK-CXL as adjuvant treatment for advanced Acanthamoeba keratitis

Corneal collagen cross-linking in mixed etiology keratitis treatment: a case of successful use

Contact Info

Product

Resources

About